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Dr. Lynch: For the dual kinase inhibitors, are you surprised
that response rates aren’t higher or more activity hasn’t been
seen, or do you think it’s just too early?
Dr. Engelman: I’m not surprised. I think, it is probably
faulty to assume there is one mechanism of resistance in a
patient and just going after a T790M mutation may fail.
Dr. Shepherd: Some of these “dual inhibitors” really aren’t
dual inhibitors. Basically, I think lapitinib is mainly a HER2
inhibitor and a weak EGFR inhibitor. It is going forward in
breast cancer where it appears to be very active as a HER2
inhibitor, but there were hardly any responses seen in the
phase 2 lung cancer trial.
Dr. Janne: Lapatinib is a very good EGFR inhibitor; how-
ever it preferentially binds the inactive conformation of
EGFR, which may be why it doesn’t work in lung cancer.
Dr. Lynch: Why do you need to block both MET and EGFR?
Why wouldn’t just inhibiting MET be enough?
Dr. Engelman: It appears that ERB B3 can get activated
either by EGFR or by MET. To kill these cancer cells, you
have to turn off ERB B3 phosphorylation, so you really need
to block both activators.
Dr. Espinoza-Delgado: Then is it correct to assume that if
you block the PI3 kinase, which is a conversion of both
pathways, you should be able to block it?
Dr. Engelman: ERB B3 is doing other things besides just
activating PI3 kinase. If you look at these addicted models,
when you inhibit EGFR, you not only down-regulate PI3
kinase, you also down-regulate ERK and down-regulate
STAT. I don’t think inhibiting PI3 kinase as a single therapy
will be nearly as effective as cutting it off at the head when
you down-regulate all those pathways that branch off of
EGFR.
Dr. Natale: Do you have a sense for the relative importance
of ligand-dependent versus ligand-independent models across
all of lung cancer?
Dr. Janne: In the presence of MET amplification, it’s ligand-
independent. That’s true not only in the resistant situation;
it’s also true in the very rare subsets. About one or two
percent of lung cancers have de novo MET amplification,
very analogous of the gastric cancer cell lines or gastric
cancer models. There are probably ligand-depend processes,
a MET and HGF/MET autocrine loop, that happen. I don’t
know what percentage this is.
Dr. Shapiro: It’s worth noting that the small molecule MET
TKIs can be divided into two classes: those that are cleaner
and those that hit other kinases as well. The ARQ197 drug is
one of the “clean” ones. One doesn’t worry too much about
overlapping toxicity with an EGFR inhibitor and side effects
associated with c-Met inhibition have overall been mild.
XL880 is an example of a compound that not only inhibits
c-Met, but is also a very potent VEGFR2 inhibitor. The
majority of toxicities are probably related to VEGFR2 inhi-
bition.
Dr. Lynch: If you think about where we’ve come in two
years it’s really been pretty remarkable how quickly things
have emerged in terms of our knowledge and understanding
of EGFR biology and the potential of these new drugs.
Dr. Shepherd: In terms of first-line treatment of patients who
have mutations, this may, indeed be an acceptable thing to do
but I just want to remind everyone that achieving a median
survival of 18 months with an EGFR inhibitor first-line may
not be as good as we can do with chemotherapy. The median
survival of patients with mutations treated with chemotherapy
in the first-line erlotinib trials was longer than 2 years. I think
we must wait for the randomized trials to answer the question
for us. It may be the right thing to do but I don’t think we
know this at this time and we need the randomized data.
Dr. Hanke: I think all this points to the importance of
looking for resistance mechanisms up front by screening cell
lines and other approaches, right up front in drug develop-
ment, which we are starting to do routinely in industry. You
have to remember that when you find these resistance mech-
anisms, you don’t yet have clinical experience to tell you if
it’s going to be important in clinical disease. We often find
mutations that don’t appear to be important in the biology of
a particular target. It’s very complex to leverage this infor-
mation before knowing the clinical significance of a particu-
lar mutation of amplification.
Dr. Hirsch: My impression is that we need to learn more
about the scheduling of the drug combinations. But what
predicts sensitivity to the drugs? How can we synergize the
effect of the drugs? What about the combination of H-stack
inhibitor and the EGFR TKIs? The preclinical data very
clearly demonstrate synergy.
Dr. Sorensen: I think the big problem with developing these
second generation EGFR TKIs is going to be identifying the
right patient population. By developing them in the acquired
resistance setting, you’re setting the bar awfully high if
you’re just hitting EGFR as we’ve discussed. You’re missing
MET and so these drugs may never make it to the point where
one is FDA approved so that you can add it to a MET
inhibitor. I’m concerned about how they’re going to make it
through the process.
Dr. Wakelee: It does get harder as we move along. We’re
doing lots of trials now looking at using the EGFR TKIs
first-line and selecting the right population, but why? These
patients are going to do better anyway. If the goal is to keep
them alive as long as possible, why use a TKI up front unless
we really believe that we’re going to somehow reduce their
responses if we use it later?
Dr. Lynch: I think the advantage of using them up front
when you have a responsive patient is that when a patient is
on gefitinib or erlotinib for 1-4 years, which some of the
patients on Dr. Sequist’s trial have been on, the quality of life
during that time is pretty good compared to having chemo-
therapy. That’s one benefit. We need randomized trials to tell
us whether it’s equivalent in terms of outcome. If it turns out
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that they are same, I think starting with an EGFR TKI could
have quality of life benefits. But we do have to make sure that
we’re not impairing the outcome.
Dr. Wakelee: Also the resistance issue is a big one. We have
all had clinical experiences with patients with good EGFR
TKI responses. When they lose that response, they sometimes
get very sick very fast and you can’t always treat them with
chemotherapy. But if you give them a less toxic platinum
doublet first-line, and their quality of life isn’t that bad, they
get benefit for a while. Single agent bevacizumab is not too
toxic either. Then we can come in with the EGFR TKI later.
Dr. Lynch: Right. The thing that you wrestle with is that the
EGFR mutant patients are exactly the patient population
that’s going to do well with carbo-tax-bevacizumab.
Dr. Sequist: We really need to do more biopsies, especially
after sequential treatments. Pre- and post- therapy biopsies
should be requirements for our trials. I know this is difficult
but we can learn so much from just one biopsy. If you think
about it, the discovery of T790 and the discovery of MET
amplification were both in only a few patients. As a commu-
nity, we all need to be committed to the biopsies.
Dr. Lynch: I agree completely but it’s hard to mandate. We
actually had to change one of our trials to make biopsies
optional because our major clinicians felt that they just
couldn’t put patients on if it required a biopsy.
Dr. Janne: In the CALGB randomized phase two trial, which
is erlotinib versus chemotherapy-erlotinib we actually man-
date, as an eligibility criteria, at least a core needle biopsy to
go on the trial. It has definitely slowed down the accrual. It’s
feasible but it definitely is slower. I think in the relapse
setting it’s that much harder. I think you need to do what you
can.
Dr. Weitzman: I too have concerns about asking patients to
subject themselves to subsequent biopsies. It would make it
easier if we could show some kind of concordance between
the first biopsy and subsequent biopsies. The other nice to
have thing would be to try and correlate the subsequent
biopsies with some more easily accessible peripheral marker.
Dr. Engelman: We don’t have to do necessarily do biopsies
at the time of progression while the patient is alive. Autopsy
series can be also useful. And autopsies are sometimes more
palatable to the patients.
Dr. Lilenbaum: Clearly the science has revolutionized the
way we understand lung cancer and the way we approach
patients. We do have clinical features that are at the very least
surrogates for the presence of some of these markers, and
given that 99 percent of physicians in practice today do not
have access to biomarkers, is it really true that if I use a
combination of smoking status, gender, ethnicity, histology,
etc. that its so much inferior to biomarkers in selecting
patients? I don’t know.
Dr. Lynch: You might be right, but the BR21 study showed
also very clearly that there were patients with squamous cell
carcinomas, even males with squamous, who have benefited
from the drug. Will you exclude, a male with squamous cell
carcinoma?
Dr. Lilenbaum: No, not in that particular setting because the
BR21 really applied to previously treated patients. I’m refer-
ring more to when you move it up front a little bit more, when
you select your patients. We’re talking about selection of
patients based on molecular markers versus clinical markers.
Do they overlap? Do they not overlap?
Dr. Lynch: The best data I’ve seen looks at never smoking,
which is probably the best marker.
Dr. Sequist: We’re just talking about EGFR and looking at
non-smoking to pick a specific type of therapy but the
ultimate goal is to be able to run a panel of genotype analyses
on each patient to know what their status is for EGFR, MET,
IGF etc and choose single agent or combination therapies
based on that. Ideally, when we understand multiple different
markers and how they affect therapy choices, trying to use
clinical characteristics for each marker is going to be too
complex.
Dr. Engelman: What we’re really looking at now is a
snapshot. We have an opportunity to make a real dent in this
type of cancer in five or ten years with continued research.
That’s what’s exciting.
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